一线治疗后进展模式与慢性淋巴细胞白血病结局相关
研究分析三项III期试验共2159例接受一线(免疫)化疗的CLL患者,按进展模式分为绝对淋巴细胞计数(ALC)升高组和淋巴结肿大(Ly)组,比较进展后至下次治疗时间(TTNT)和总生存(OS)。结果显示Ly组TTNT更短, unfit患者Ly组OS更差,且Ly组生活质量受损更常见。
核心结论
- 进展表现为淋巴结肿大的CLL患者TTNT显著更短、OS更差且生活质量更差。
研究设计与样本
- 基于德国CLL研究组三项III期试验(CLL8、CLL10、CLL11)共2159例接受一线(免疫)化疗(FCR、FC、CLB、CLB-R、CLB-Ob)的患者数据分析。
主要发现
- 241例因ALC升高进展,727例因淋巴结肿大进展,其中329例同时存在两种进展模式。
临床怎么用
- 进展模式可能帮助医生更好地估计进展期CLL患者的临床病程。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In CLL, progressive disease (PD) following remission after first line treatment can present with varying phenotypes. We hypothesized that the mode of PD correlates with clinical outcomes. Data from three phase III trials of the German CLL Study Group (GCLLSG) (CLL8, CLL10, CLL11) including a total of 2159 patients receiving first line (immuno)-chemotherapy (FCR, FC, CLB, CLB-R, CLB-Ob) were analyzed. Patients were categorized as "ALC" if PD was due to increasing absolute lymphocyte count, or as "Ly" if due to lymphadenopathy. A group of 241 patients progressed with ALC, and 727 progressed with Ly, including 329 who progressed on both modalities. In fit patients, median TTNT after PD in the Ly group was 12.3 months vs 17.0 months in the ALC group (HR 1.299 [1.036-1.628]; P = .024). Median OS after PD was 45.1 months in the Ly group and 42.4 months in the ALC group (HR=1.023 [0.753-1.389]; P = .885). For unfit patients, median TTNT in the Ly group was 11.7 months vs 21.4 months in the ALC group (HR 1.357 [1.051-1.753]; P = .019). Median OS was 42.8 months in the Ly group and not reached in the ALC group (HR 1.851 [1.280-2.677]; P = .001). Patients in the Ly group more frequently showed impairment of quality of life (QoL). This analysis demonstrates that patients with progressive lymphadenopathy have a significantly shorter TTNT, OS and less favorable QoL. Our findings might help physicians to better estimate the clinical course of a progressing CLL patient.
引用
- Al-Sawaf O, Bazeos A, Robrecht S, et al. Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL). Am J Hematol. 2019. PMID: 31222797. doi:10.1002/ajh.25561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。